Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth

Fayi Wu; Stephanie O. Peacock; Shuyun Rao; Sandra K. Lemmon; Kerry L. Burnstein

doi:10.1074/jbc.M112.390963

Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth

Fayi Wu, Stephanie O. Peacock, Shuyun Rao, Sandra K. Lemmon, Kerry L. Burnstein

Molecular and Cellular Pharmacology

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.

Original language	English (US)
Pages (from-to)	5463-5474
Number of pages	12
Journal	Journal of Biological Chemistry
Volume	288
Issue number	8
DOIs	https://doi.org/10.1074/jbc.M112.390963
State	Published - Feb 22 2013

ASJC Scopus subject areas

Biochemistry
Molecular Biology
Cell Biology

Access to Document

10.1074/jbc.M112.390963

Fingerprint Dive into the research topics of 'Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth'. Together they form a unique fingerprint.

Cite this

Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth. / Wu, Fayi; Peacock, Stephanie O.; Rao, Shuyun; Lemmon, Sandra K.; Burnstein, Kerry L.

In: Journal of Biological Chemistry, Vol. 288, No. 8, 22.02.2013, p. 5463-5474.

Research output: Contribution to journal › Article › peer-review

@article{f86d6cc5b36a444d99d27b9e60cb69a1,

title = "Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth",

abstract = "Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.",

author = "Fayi Wu and Peacock, {Stephanie O.} and Shuyun Rao and Lemmon, {Sandra K.} and Burnstein, {Kerry L.}",

year = "2013",

month = feb,

day = "22",

doi = "10.1074/jbc.M112.390963",

language = "English (US)",

volume = "288",

pages = "5463--5474",

journal = "Journal of Biological Chemistry",

issn = "0021-9258",

publisher = "American Society for Biochemistry and Molecular Biology Inc.",

number = "8",

}

TY - JOUR

T1 - Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth

AU - Wu, Fayi

AU - Peacock, Stephanie O.

AU - Rao, Shuyun

AU - Lemmon, Sandra K.

AU - Burnstein, Kerry L.

PY - 2013/2/22

Y1 - 2013/2/22

N2 - Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.

AB - Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84874324273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874324273&partnerID=8YFLogxK

U2 - 10.1074/jbc.M112.390963

DO - 10.1074/jbc.M112.390963

M3 - Article

C2 - 23281476

AN - SCOPUS:84874324273

VL - 288

SP - 5463

EP - 5474

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 8

ER -

Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this